Gordon Bunyan from Australia is currently a Vice-President of the International Diabetes Federation (IDF) for the 2009-2012 triennium. In the past, he has been Chair of the IDF Western Pacific Region (2006-2009).
Susana Feria from Uruguay is a Vice-President of the International Diabetes Federation (IDF), and a past Chair of the IDF South and Central American Region (SACA).
She was elected as Chairperson of SACA Region in 2003 and reelected in 2006. Previously in 2000 she was elected delegate of Uruguay as IDF Country Representative. She was also on the IDF Board of Management for the period 2000-2009.
Dr Kaushik Ramaiya from Tanzania is currently a Vice-President of the International Diabetes Federation (IDF). He is a Consultant Physician and Assistant Medical Administrator at Shree Hindu Mandal Hospital, Dar es Salaam, Tanzania, and Honorary Lecturer at the Department of Medicine of Muhimbili University of Health & Allied Sciences (MUHAS), Dar es Salaam.
Dr Jonathan Betz Brown from the USA is currently a Vice-President of the International Diabetes Federation (IDF) for the 2009-2012 triennium, and Chair of the IDF Task Force on Diabetes Health Economics, which is conducting studies of the economic impact of diabetes in low and middle-income countries around the world.
Ms Anne Belton from Canada is a diabetes nurse educator and education consultant. She is a Vice-President of the International Diabetes Federation for 2013-15. She was an IDF Vice-President for 2009-12 and has been a member of the Federation's Consultative Section on Education since 2000.
Diabetes is a serious health condition that poses challenges to a person’s daily life, emotional well-being and perceived quality of life. It increases one’s risk of developing long-term diabetes and other health-related complications and encountering an early death. To meet the global demand for effective diabetes prevention, quality care, and effective treatment strategies, adequate resources must be allocated.
In October 2008, the International Diabetes Federation Clinical Guidelines Task Force, in conjunction with the SMBG International Working Group, convened a workshop in Amsterdam to address the issue of SMBG utilization in people with type 2 diabetes (T2M) that is not treated with insulin.
Pregnancy is associated with changes in insulin sensitivity which may lead to changes in plasma glucose levels. For women with known diabetes or for women who develop diabetes during the pregnancy, these changes can put outcomes at risk. This guideline deals with the means of identifying women for whom such problems are new, and helping them, as well as women already known to have diabetes, to achieve the desired outcome of a healthy mother and baby.